Skip to search formSkip to main contentSkip to account menu

eculizumab

Known as: Immunoglobulin, Anti-(Human Complement C5 Alpha-Chain) (Human-Mouse Monoclonal 5G1.1 Heavy Chain), Disulfide with Human-Mouse Monoclonal 5G.1.1 Light Chain, Dimer, monoclonal antibody anti-C5, h5G1.1 
A monoclonal antibody used to prevent red blood cells from being destroyed in patients with paroxysmal nocturnal hemoglobinuria (PNH), a red blood… 
National Institutes of Health

Related topics

Related topics

6 relations
30 ML eculizumab 10 MG/ML Injection30 ML eculizumab 10 MG/ML Injection [Soliris]antigen binding

Narrower (1)

Alexion

Broader (2)

AntibodiesAntibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
2016
2016
A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor.
peaks characteristic of MSU crystals in one control patient with OA who did not meet the classification criteria for gout [6] is… 
Review
2013
Review
2013
The use of eculizumab in renal transplantation
The complement system plays a vital role in mediating disease processes within renal allografts. Eculizumab is a humanized… 
2013
2013
Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome
Dear Editor, Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) caused by dysregulation of the… 
2013
2013
Treatment of Moderate to Severe Hidradenitis Suppurativa
TO THE EDITOR: The phase 2 randomized trial by Kimball and colleagues (1), which claims a benefit of adalimumab in hidradenitis… 
2013
2013
Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
2012
2012
Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab
BackgroundAtypical hemolytic uremic syndrome (aHUS) is characterized by the triad of microangiopathic hemolytic anemia… 
2012
2012
Preservation of Renal Function in Atypical Hemolytic Uremic Syndrome by Eculizumab: A Case Report
Genetic mutations in complement components are associated with the development of atypical hemolytic uremic syndrome (aHUS), a… 
Highly Cited
2011
Highly Cited
2011
Eculizumab in Acute Recurrence of Thrombotic Microangiopathy After Renal Transplantation
Renal thrombotic microangiopathy (TMA) is a severe complication of systemic lupus erythematosus (SLE), which is associated with… 
Highly Cited
2011
Highly Cited
2011
Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab.
Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by complement hyperactivation secondary to defects in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)